_{*Full Eligibility Terms and Conditions: Direct purchase option is only available for KEPPRA® (levetiracetam) tablets prescriptions. Pricing for a month supply is based on patients taking 120 tablets of either 250, 500, or 750 mg per 30 days or 60 tablets of 1,000 mg per 30 days. Pricing for a 3-month supply is based on patients taking 360 tablets of either 250, 500, or 750 mg per 90 days or 180 tablets of 1,000 mg per 90 days. Patient must have a valid prescription consistent with the FDA-approved product labeling for KEPPRA to participate in the UCB Direct program for KEPPRA. The UCB Direct program for KEPPRA is available to residents of the United States and all United States Territories only. Program is not available where prohibited by law. The UCB Direct program for KEPPRA operates outside of any third-party insurance. Neither the patient nor the pharmacy nor anyone else acting on the patient’s behalf may submit any claim for reimbursement for product dispensed pursuant to this program to any third-party payer, including Medicare, Medicaid, or any other federal or state healthcare program. Out-of-pocket expenses incurred when using this program cannot be applied toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP). The UCB Direct program for KEPPRA does not include all Manufacturer products. Eligible patients may purchase the following Manufacturer products from the program: KEPPRA tablets. The UCB Direct program for KEPPRA is not health insurance. Limitations may apply. The UCB Direct program for KEPPRA cannot be combined with any other savings, free trial, or similar offer for the specified prescription. Manufacturer reserves the right to rescind, revoke, or amend this program without notice.}